MYASTHENIA Cohort: Myasthenia Gravis: diagnostic, prognostic and therapy response markers
The course and degree of severity of myasthenia gravis (MG) vary greatly from individual to the next. To date there have been no clinical, genetic or immunological markers that permit a prediction of the form the myasthenia will take and thus a prognosis. By means of the myasthenia cohort, prognostic parameters are to be identified that allow the course (ocular, generalized, myasthenic crisis), the response to treatment (pyridostigmine, steroids, immunosuppressants, thymectomy) and the long-term course to be predicted early on. In addition, biomarkers are to be identified which predict disease activity (remissions and/or exacerbation of the disease). Furthermore, new scientific hypotheses and findings are to be investigated on the basis of the study population, which is to be systematically examined for a period of ten years and is expected to be very well defined, both clinically and paraclinically.
Principle Investigator: Prof. Dr. Andreas Meisel (WG Cerebrovascular Diseases, NCRC, CSB, Neurology CCM)
Course of the study: 03/2011
Hoffmann, S., J. Ramm, U. Grittner, S. Kohler, J. Siedler, and A. Meisel. "Fatigue in Myasthenia Gravis: Risk Factors and Impact on Quality of Life." Brain Behav 6, no. 10 (Oct 2016): e00538. http://dx.doi.org/10.1002/brb3.538. Link
Stascheit, F., B. Hotter, S. Hoffmann, S. Kohler, S. Lehnerer, A. Sputtek, and A. Meisel. "Calprotectin as Potential Novel Biomarker in Myasthenia Gravis." J Transl Autoimmun 4 (2021): 100111. Link.